GPI compete with a wider use of ADP inhibitors and novel anticoagulant drugs although GPI use has greatly narrowed;

Ischemic and hemorrhagic risks need be carefully evaluated along with thrombocytopenia and its prognostic significance;

There are positive elements in GPI use: efficacy, rapid onset and reversibility of action, absence of pharmacogenomic variability, pharmacoeconomic considerations;

All these elements should be evaluated when selecting these agents for therapeutics.